TITLE

Efficacy and Toxicity of Pemetrexed or Gemcitabine Combined with Cisplatin in the Treatment of Patients with Advanced Non-small Cell Lung Cancer

AUTHOR(S)
Xingsheng Hu; Shunchang Jiao; Shucai Zhang; Zhehai Wang; Mengzhao Wang; Cheng Huang; Rongsheng Zheng; Kai Li; Jie Wang; Yajie Wang; Xuenong Ouyang; Wenguang Lv; Gang Cheng; Chunhong Hu; Rongcheng Luo; Yan Sun
PUB. DATE
October 2012
SOURCE
Chinese Journal of Lung Cancer;Oct2012, Vol. 15 Issue 10, p569
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and objective Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC). Methods 251 patients were randomly divided into pemetrexed combined with cisplatin group (PP group) with 127 cases and gemcitabine combined with cisplatin group (GP group) with 124 cases. PP group received pemetrexed 500 mg/m2 iv infusion d1 and cisplatin 75 mg/m2 iv infusion d1, whereas GP group received gemcitabine 1,000 mg/m2 iv infusion d1,8 and cisplatin 75 mg/m2 iv infusion d1. The treatment cycle was once every three weeks. In addition, folic acid, vitamin B12, and dexamethasone were administered in both groups. Results The total clinical effective rates in PP group and GP group were 25.20% and 17.74%, respectively. The total efficiencies of non-squamous cell carcinoma were 27.62% and 16.00%. The tumor progression duration in these two groups was 6.5 and 5.6 months, respectively. The median survival time in the two groups was 16.9 and 17.0 months, respectively, with 59.62% and 65.87% survival rates of 1 year and 27.28% and 27.93% survival rates of 2 years, respectively. The total efficacy of non-squamous cell carcinoma in the PP group was significantly higher than that in GP group. The results were statistically significant. However, there were no significant differences in total response rates, tumor progression duration, and median survival rates of 1 and 2 years. The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group. The results were statistically significant. Conclusion The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group. Therefore, pemetrexed combined with cisplatin can be used as a safe and effective drug for clinical first-line treatment for previously untreated NSCLC.
ACCESSION #
82716701

 

Related Articles

  • Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience. Vitale, Felice V; Malaponte, Emilia; Calì, Stefania; Antonelli, Giovanna; Panebianco, Vincenzo; Blandino, Rosario; Ferraù, Francesco // Journal of Oncology Pharmacy Practice;Sep2013, Vol. 19 Issue 3, p202 

    Background: Mitomycin and irinotecan are widely used in the treatment of colorectal cancer, furthermore both of these drugs are active agents against nonsmall cell lung cancer and their combination has shown synergism in preclinical studies. The aim of the study was to evaluate the efficacy and...

  • Single-Dose Fosaprepitant. Ershler, William B. // Clinical Oncology Alert;Jun2013, Vol. 29 Issue 6, p41 

    Synopsis: Current strategies to prevent chemotherapy-induced nausea and vomiting frequently include a 3-day course of aprepitant. In a multicenter trial from Japan, administration of a single dose of the aprepitant prodrug fosaprepitant, when used in combination with granisetron and...

  • The Role of Capecitabine in Locally Advanced Rectal Cancer Treatment. Fernandez-Martos, Carlos; Nogué, Miguel; Cejas, Paloma; Moreno-García, Víctor; Machancoses, Ana Hernández; Feliu, Jaime // Drugs;2012, Vol. 72 Issue 8, p1057 

    Preoperative infusional 5-fluorouracil (5-FU) and concurrent radiation therapy (RT) followed by total mesorectal surgery is the current standard of care for locally advanced rectal cancer (LAR). When compared with postoperative 5-FU-based chemoradiation, this strategy is associated with...

  • Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Hoang, Tien; Campbell, Toby; Zhang, Chong; Kim, KyungMann; Kolesar, Jill; Oettel, Kurt; Blank, Jules; Robinson, Emily; Ahuja, Harish; Kirschling, Ron; Johnson, Peter; Huie, Michael; Wims, Mary; Larson, Martha; Hernan, Hilary; Traynor, Anne // Investigational New Drugs;Feb2014, Vol. 32 Issue 1, p195 

    Introduction The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC) patients. Methods Eligibility criteria included recurrent/metastatic NSCLC, having received 2...

  • Chemotherapy Prior to Chemoradiotherapy for Neoadjuvant Rectal Cancer Treatment. Ershler, William B. // Clinical Oncology Alert;Nov2012, Vol. 28 Issue 11, p81 

    The article describes about a novel treatment regimen used for "Induction chemotherapy" followed by chemoradiotherapy for Neoadjuvant Rectal Cancer Treatment and describes about the capecitabine/oxaliplatin (CAPEOX) chemotherapy followed by CRT all prior to total mesorectal excision (TME). The...

  • Review finds home chemotherapy as safe as hospital treatment.  // Cancer Nursing Practice;Feb2011, Vol. 10 Issue 1, p5 

    The article discusses a Bupa-commissioned research that reviewed 90 studies and concluded that when appropriate, home chemotherapy is as safe as treatment provided at outpatient or day-units and hospitals.

  • Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Poklepovic, Andrew; Youseffian, Leena; Winning, Mary; Birdsell, Christine; Crosby, Nancy; Ramakrishnan, Viswanathan; Ernstoff, Marc; Roberts, John // Investigational New Drugs;Aug2013, Vol. 31 Issue 4, p937 

    Purpose Preclinical studies in human melanoma cell lines and murine xenograft tumor models suggest that the proteasome inhibitor bortezomib enhances the activity of the cytotoxic agent dacarbazine. We performed a phase I trial of bortezomib and dacarbazine in melanoma, soft tissue sarcoma, and...

  • Abraxane Receives New Indication for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer When Curative Surgery or Radiation Therapy Is Not an Option. Lederman, Lynne // American Health & Drug Benefits;Apr2013, Vol. 6 Issue 3, p19 

    The article discusses the U.S. Food and Drug Administration (FDA) approval for abraxane as a first-line treatment in combination with carboplatin for metastatic or advanced non-small-cell lung cancer (NSCLC) in patients not recommended for radiation therapy or curative surgery. Topics discussed...

  • Docetaxel and Cisplatin Regimen for Non-Small Cell Lung Cancer. Yang, Jessie; Solimando, Jr, Dominic A.; Waddell, J. Aubrey // Hospital Pharmacy;Jul2013, Vol. 48 Issue 7, p550 

    The article offers information on adjuvant and neoadjuvant treatment of non-small cell lung cancer and also focuses on preparation, dispensing and administration of docetaxel and cisplatin regimen. It discusses the investigational and commercially availbale agents used for treatment of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics